全文获取类型
收费全文 | 237篇 |
免费 | 11篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 12篇 |
妇产科学 | 2篇 |
基础医学 | 33篇 |
口腔科学 | 5篇 |
临床医学 | 31篇 |
内科学 | 37篇 |
皮肤病学 | 8篇 |
神经病学 | 9篇 |
特种医学 | 36篇 |
外科学 | 10篇 |
综合类 | 35篇 |
预防医学 | 12篇 |
眼科学 | 3篇 |
药学 | 4篇 |
中国医学 | 1篇 |
肿瘤学 | 11篇 |
出版年
2022年 | 4篇 |
2021年 | 3篇 |
2020年 | 4篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 8篇 |
2013年 | 6篇 |
2012年 | 18篇 |
2011年 | 18篇 |
2010年 | 15篇 |
2009年 | 7篇 |
2008年 | 13篇 |
2007年 | 12篇 |
2006年 | 12篇 |
2005年 | 6篇 |
2004年 | 7篇 |
2003年 | 2篇 |
2002年 | 4篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 9篇 |
1997年 | 6篇 |
1996年 | 16篇 |
1995年 | 13篇 |
1994年 | 5篇 |
1993年 | 7篇 |
1992年 | 1篇 |
1991年 | 5篇 |
1989年 | 7篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1977年 | 1篇 |
1975年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有250条查询结果,搜索用时 7 毫秒
31.
32.
单克隆抗体BDI-I导向的阿霉素白蛋白毫微球对人膀胱癌细胞的特异杀伤活性 总被引:13,自引:0,他引:13
用化学偶联法将抗人膀胱癌单克隆抗体分子偶联到阿霉素白蛋白毫微球上,构建了一个有靶向杀伤性的免疫毫微球,即:阿霉素白蛋白载单克隆抗体毫微球(ADR-NP-Ab)。改变阿霉素毫微球和单克隆抗体的反应分子比,确定了制备该免疫毫微球的最佳条件。经免疫荧光检测及显微照像分析证明,免疫毫微球可有效地和人膀胱癌细胞结合。体外杀伤试验表明,此免疫毫微球对靶细胞EJ有高度特异杀伤活性,而对无关的人直肠癌Lovo细胞则无明显作用。 相似文献
33.
34.
35.
Background
Medical Termination of Pregnancy (MTP) is a commonly performed during the first trimester. Dilatation and Evacuation (D & E) mandates rapid dilatation of cervix with metal dilators, which requires anaesthesia and may be associated with trauma to the uterus, cervix and later cervical incompetence. The problem of rapid cervical dilatation is obviated with intravaginal misoprostol.Methods
Intravaginal misoprostol tablet 200 microgram was inserted, a night prior to MTP to ripen the cervix. Cervix was dilated with metal dilators only in cases where cervix did not loosen up sufficiently. Products of conception were removed by suction.Results
Out of 108 cases cervical dilatation was not required in 96 cases (88.9%).Conclusion
Intravaginal misoprostol 200 microgram proved effective as a priming agent prior to MTP in the first trimester.Key Words: Misoprostol, MTP 相似文献36.
Epidemiology of headache 总被引:5,自引:0,他引:5
BK Rasmussen 《Cephalalgia : an international journal of headache》1995,15(1):44-67
37.
38.
39.
Winton EF; Srinivasiah J; Kim BK; Hillyer CD; Strobert EA; Orkin JL; Swenson RB; McClure HM; Myers LA; Saral R 《Blood》1994,84(1):65-73
Using a recently developed hepsulfam-induced pancytopenia model in rhesus macaques, we have studied the effects of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on marrow regeneration. Control animals were given hepsulfam (1.5 g/m2 by a single 30-minute intravenous [i.v.] injection, n = 4), while study animals received hepsulfam followed by rhIL-6, rhIL-3, or a combination of rhIL-6 and rhIL-3 (n = 3 per study group). Each cytokine was administered by once- daily subcutaneous (SC) injection (15 micrograms/kg/d) for 3 weeks beginning the day after chemotherapy (days 2 through 22). Mean platelet counts in control animals were < 100,000/microL on days 15 through 24, with 50% of the counts < 50,000/microL and two of four animals requiring platelet transfusion. In the rhIL-6- and rhIL-6/rhIL-3- treated groups, the nadir mean platelet counts were 164,000 +/- 58,700/microL and 162,300 +/- 23,800/microL, respectively, and occurred on day 15. Platelet counts in the rhIL-3-treated group were similar to those in controls. Mean absolute neutrophil counts (ANCs) < 1,000/microL occurred on days 10 through 29 in control animals, days 8 through 15 in rhIL-6-treated animals, and days 6 through 8 and 13 in rhIL-6/rhIL-3-treated animals. The frequency of ANCs < 500/microL was significantly less in the rhIL-6- and rhIL-6/rhIL-3-treated groups versus control groups (2.7 +/- 0.6 and 2.0 +/- 1.0 vs 7.0 +/- 1.4 occurrences, respectively; P < .05). rhIL-3-treated animals had ANCs similar to those in controls; one animal died with septicemia on day 21. Monkeys receiving rhIL-6 were significantly more anemic during the cytokine administration period; however, the anemia resolved by day 24. Coadministration of rhIL-3 and rhIL-6 partially corrected the anemia. The data indicate that rhIL-6 prevents significant thrombocytopenia and shortens the neutropenic period in this chemotherapy model. 相似文献
40.